Literature DB >> 6136396

Sulfasalazine. Adverse effects and desensitization.

S L Taffet, K M Das.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6136396     DOI： 10.1007/bf01296907

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  104 in total

1.  Megaloblastic anaemia associated with sulphasalazine treatment.

Authors:  M Bateson
Journal:  Br Med J       Date:  1977-07-16

2.  Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

Authors:  R E Pounder; E R Craven; J S Henthorn; J M Bannatyne
Journal:  Gut       Date:  1975-03       Impact factor: 23.059

3.  [Salazosulfapyridine-induced lupus erythematosus syndrome in ulcerative colitis (author's transl)].

Authors:  B H Jaup
Journal:  Dtsch Med Wochenschr       Date:  1978-07-28       Impact factor: 0.628

4.  Drug agranulocytosis. A case study.

Authors:  V E Darling
Journal:  Nurs Times       Date:  1965-09-03

5.  Acute massive hepatic necrosis with fatal liver failure.

Authors:  C M Caravati; T H Hooker
Journal:  Am J Dig Dis       Date:  1971-09

6.  Sulfasalazine-induced exacerbation of ulcerative colitis.

Authors: 
Journal:  N Engl J Med       Date:  1982-07-29       Impact factor: 91.245

7.  Biochemical and clinical changes in rheumatoid arthritis: their relation to the action of antirheumatoid drugs.

Authors:  J S Dixon
Journal:  Semin Arthritis Rheum       Date:  1982-11       Impact factor: 5.532

8.  Salazopyrin-induced eosinophilic pneumonia.

Authors:  S Berliner; A Neeman; Y Shoenfeld; M Eldar; I Rousso; U Kadish; J Pinkhas
Journal:  Respiration       Date:  1980       Impact factor: 3.580

9.  Sulphasalazine and male infertility: reversibility and possible mechanism.

Authors:  S Toovey; E Hudson; W F Hendry; A J Levi
Journal:  Gut       Date:  1981-06       Impact factor: 23.059

10.  Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy.

Authors:  J L THIRKETTLE; K R GOUGH; A E READ
Journal:  Lancet       Date:  1963-06-29       Impact factor: 79.321
View more
  64 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

3.  Is mesalamine safe?

Authors:  Kenneth W Schroeder
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

Review 4.  Drug management of ulcerative colitis.

Authors:  M A Kamm; A Senapati
Journal:  BMJ       Date:  1992-07-04

5.  Desensitization for sulfasalazine-induced skin rash in a patient with ulcerative colitis.

Authors:  K Akahoshi; Y Chijiiwa; T Kabemura; H Okabe; Y Akamine; H Nawata
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

Review 6.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

Review 7.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

8.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 9.  Anemia and inflammatory bowel diseases.

Authors:  Fernando Gomollón; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

10.  Olsalazine in maintenance of clinical remission in patients with ulcerative colitis.

Authors:  J P Wright; E A O'Keefe; L Cuming; K Jaskiewicz
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.